{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:23:24Z","timestamp":1753356204076},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":2926,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1093\/annonc\/mdr472","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T08:43:25Z","timestamp":1324025005000},"page":"viii16-viii18","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S8","title":["Designing early detection programs for ovarian cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"N.","family":"Urban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr472_bb0010","unstructured":"A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women. 2010; http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01121640 (date last accessed 6 June 2011)"},{"key":"10.1093\/annonc\/mdr472_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biostatistics\/4.1.27","article-title":"A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker","volume":"4","author":"McIntosh","year":"2003","journal-title":"Biostatistics"},{"key":"10.1093\/annonc\/mdr472_bb0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdr472_bb0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0b013e31819cda77","article-title":"Results from four rounds of ovarian cancer screening in a randomized trial","volume":"113","author":"Partridge","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdr472_bb0030","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1093\/annonc\/mdr472_bb0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J Clin Lab Anal"},{"key":"10.1093\/annonc\/mdr472_bb0040","first-page":"111","article-title":"HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses","volume":"11","author":"Abdel-Azeez","year":"2010","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1093\/annonc\/mdr472_bb0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/djp438","article-title":"Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study","volume":"102","author":"Anderson","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr472_bb0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-10-0195","article-title":"Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens","volume":"4","author":"Cramer","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1093\/annonc\/mdr472_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1940-6207.CAPR-10-0193","article-title":"for the PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer","volume":"4","author":"Zhu","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1093\/annonc\/mdr472_bb0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","article-title":"Use of a symptom index, CA125 and HE4 to predict ovarian cancer","volume":"116","author":"Andersen","year":"2010","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419388696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419388696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/Suppl_8\/viii6\/601850\/mdr472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:52:57Z","timestamp":1582181577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419388696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":11,"alternative-id":["S0923753419388696"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr472","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}